---
title: "Cardiovascular disease biotech Scribe Therapeutics prices upsized IPO at $15, the high end of the range"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293756130.md"
description: "Cardiovascular biotech Scribe Therapeutics priced its upsized IPO at $15 per share, the high end of the range, raising $129 million from 8.6 million shares. The offering exceeded initial expectations by 1.4 million shares, with Eli Lilly participating in $10 million. A concurrent private placement will raise an additional $7.5 million from Sanofi. SCTX will trade on Nasdaq."
datetime: "2026-07-24T12:21:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293756130.md)
  - [en](https://longbridge.com/en/news/293756130.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293756130.md)
generator: "portal-rs"
---

# Cardiovascular disease biotech Scribe Therapeutics prices upsized IPO at $15, the high end of the range

Scribe Therapeutics, a Phase 1 biotech developing CRISPR genetic therapies for high cholesterol, raised $129 million by offering 8.6 million shares at $15, the high end of the $13 to $15 range. The company offered 1.4 million more shares than anticipated. Existing shareholder Eli Lilly had indicated on $10 million of the IPO (7.8% of the deal). The company also plans to raise an additional $7.5 million in a concurrent private placement to Sanofi.

Scribe Therapeutics is developing in vivo CRISPR-based therapies aimed at extending healthy lifespan through disease prevention, with an initial focus on cardiovascular and metabolic disease. Its lead candidate, STX-1150, uses an epigenetic silencing approach to durably lower LDL-C by repressing PCSK9 expression, without permanently altering DNA. It's currently in a first-in-human trial in Australia under TGA clearance, with initial data expected in the first half of 2027. Two follow-on programs, STX-1200 and STX-1400, apply the company's XE gene-editing technology to target Lp(a) and triglycerides as additional drivers of atherosclerotic cardiovascular disease, and are supported in part by CIRM grant funding, with Phase 1 trials anticipated in 2027 and 2028.

The Alameda, CA-based company will trade on the Nasdaq under the symbol SCTX. Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities acted as joint bookrunners on the deal.

### Related Stocks

- [SNY.US](https://longbridge.com/en/quote/SNY.US.md)
- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [LLYZ.US](https://longbridge.com/en/quote/LLYZ.US.md)
- [LLYX.US](https://longbridge.com/en/quote/LLYX.US.md)
- [ELIS.US](https://longbridge.com/en/quote/ELIS.US.md)
- [ELIL.US](https://longbridge.com/en/quote/ELIL.US.md)
- [GS.US](https://longbridge.com/en/quote/GS.US.md)
- [WFC.US](https://longbridge.com/en/quote/WFC.US.md)
- [SNYNF.US](https://longbridge.com/en/quote/SNYNF.US.md)
- [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md)
- [WFC-D.US](https://longbridge.com/en/quote/WFC-D.US.md)
- [WFC-L.US](https://longbridge.com/en/quote/WFC-L.US.md)
- [WFC-Y.US](https://longbridge.com/en/quote/WFC-Y.US.md)
- [WFC-C.US](https://longbridge.com/en/quote/WFC-C.US.md)
- [WFC-Z.US](https://longbridge.com/en/quote/WFC-Z.US.md)
- [WFC-A.US](https://longbridge.com/en/quote/WFC-A.US.md)

## Related News & Research

- [Why Is Omniab Stock Rallying After Eli Lilly Deal?](https://longbridge.com/en/news/296113651.md)
- [Eli Lilly Is Building a Weight Loss Drug for Every Kind of Patient](https://longbridge.com/en/news/296005917.md)
- [How Eli Lilly’s Global Vault CRM Rollout At Veeva Systems (VEEV) Has Changed Its Investment Story](https://longbridge.com/en/news/296430987.md)
- [Elyxium Wealth LLC Has $7.30 Million Position in Eli Lilly and Company $LLY](https://longbridge.com/en/news/296017075.md)
- [Eli Lilly EVP, international president Patrik Jonsson disposes of 6,500 shares worth $7.64 million](https://longbridge.com/en/news/296266483.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**